The city of Glendale, California, currently has 8 active clinical trials seeking participants for Healthy research studies.
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
Recruiting
A study to demonstrate the safety and tolerability of AZD1163 when administered intravenously and subcutaneously in healthy participants.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/24/2024
Locations: Research Site, Glendale, California
Conditions: Healthy Volunteers
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with severe Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
Male
Ages:
Between 18 years and 60 years
Trial Updated:
04/22/2024
Locations: California Clinical Trials Medical Group (CCTMG), Glendale, California
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects
Recruiting
This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/16/2024
Locations: California Clinical trials medical group/PAREXEL, Glendale, California
Conditions: Healthy Participants
A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
Recruiting
The purpose of the study is to estimate the relative bioavailability of 2 new UCB0599 formulations under elevated and normal gastric pH conditions in healthy participants (Part A) and to asess the safety, tolerability and pharmacokinetics of UCB0599 in healthy participants of Japanese and Chinese origins (Part B).
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
03/13/2024
Locations: Up0073 10001, Glendale, California
Conditions: Healthy Study Participants
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
Recruiting
This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy participants.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
03/07/2024
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD)
Recruiting
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment. Part A is focused on healthy participants. Part B of the study is focused on participants who are known to have NAFLD and a specific variant of the PNPLA3 gene. The aim of the study is to see how safe, tolerable and effective the study... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2024
Locations: California Clinical Trials Medical Group, Glendale, California
Conditions: Healthy Volunteers, Non-alcoholic Fatty Liver Disease (NAFLD)
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Recruiting
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4144 administered orally in healthy participants.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2024
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/05/2024
Locations: Research Site, Glendale, California
Conditions: Healthy Participants